NCT02240966

Symptoms and Clinical Signs of Hypogonadism in Testicular Cancer Survivors

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 200 (actual)
• Sponsor: Rigshospitalet, Denmark · Academic / Other
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the prevalence of signs and symptoms of hypogonadism in three groups of testicular cancer survivors.

Detailed description

Recent studies have shown that metabolic syndrome is common among testicular cancer. Patients with low levels of testosterone appear to be at higher risk of metabolic syndrome. A substantial number of testicular cancer survivors might be in a state of "compensated hypogonadism" with testosterone levels low in the normal range due to an increased LH-drive from the pituitary gland. Whether this specific groups of testicular cancer survivors are at increased risk of cardio-vascular disease and might benefit from testosterone substitution is yet to be clarified.

Conditions

• Metabolic Syndrome
• Hypogonadism
• Cardio-vascular Disease

Timeline

• Start date: 2014-08-01
• Primary completion: 2016-07-01
• Completion: 2016-07-01
• First posted: 2014-09-16
• Last updated: 2016-07-14

Locations

1 site across 1 country: Denmark